Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers

Pharmacotherapy

Volumn 20, Issue 3, 2000, Pages 330-335

  Grasela, Dennis M ^a   LaCreta, Frank P ^a   Kollia, Georgia D ^a   Randall, Diane M ^a   Uderman, Howard D ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; AMITRIPTYLINE; CARBAMAZEPINE; CISAPRIDE; CLOMIPRAMINE; CLOZAPINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; DIAZEPAM; DILTIAZEM; ERYTHROMYCIN; ETHINYLESTRADIOL; FELODIPINE; GATIFLOXACIN; IMIPRAMINE; LIDOCAINE; MEVINOLIN; MIDAZOLAM; NEFAZODONE; NIFEDIPINE; PARACETAMOL; PROPAFENONE; QUINIDINE; RITONAVIR; SERTRALINE; SIMVASTATIN; TERFENADINE; UNINDEXED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RESEARCH; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; STEADY STATE;

EID: 0034101807     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.4.330.34878     Document Type: Article

References (25)

1. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost of illness model. Arch Intern Med 1995;155:1949-56.
2. Classen DC, Pestotnik SL, Scott Evans R, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
3. Porter J, Jick H. Drug-related deaths among medical inpatients. JAMA 1977;237:879-81.
4. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse drug events prevention study group. JAMA 1997;277:307-11.
5. Johnson MD, Newkirk G, White JR Jr. Clinically significant drug interactions. Postgrad Med 1999;105:193-222.
6. Thummel KE, Shenn DD, Podoll TD, et al. Use of midazolam as a human cytochrome P4503A probe. 1. In vitro-in vivo correlation in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
7. Kashuba AD, Bertino JS, Rocci ML Jr, et al. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998;64(3):269-77.
8. Nakashima M, Uematsu T, Kosuge K, et al. Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone in humans. J Antimicrob Chemother 1995;39:2635-40.
9. Gohler K, Stahlberg HJ. Safety, tolerance and food effect after single and multiple oral doses of gatifloxacin, a new fluoroquinolone, in healthy volunteers [abstr]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28-October 1, 1997.
10. Bristol-Myers Squibb Co. A study to assess the potential for inhibition of cytochrome P4503A4-catalyzed testosterone 6β-hydroxylase activity by the test substance BMS-206584. Data on file, 1998.
11. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982:409-17.
12. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8:509-34.
13. Farmen RH, Muniak JF. Management of pharmacokinetic data using HP-3357 mainframe IBM interfacing. Drug Information J 1987;21:141-52.
14. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmaco Ther Toxicol 1991;29(1):1-8.
15. Grasela DM, Birkhofer MJ, Mangold B, et al. Open-label nonrandomized study of the effects of gatifloxacin on the pharmacokinetics and pharmacodynamics of concomitantly administered warfarin in healthy subjects. Princeton, NJ: Bristol-Myers Squibb Pharmaceutical Research Institute, 1998.
16. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998;12(6):485-94.
17. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998;64(3):278-85.
18. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64(2):133-43.
19. McLellan RA, Drobitch RK, Monshouwer M, Renton KW. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996;24(10):1134-8.
20. Hosaka M, Yasue T. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992;36(10):2108-17.
21. Tomizawa H, Teteda K, Miyazaki S, Yamaguchi K. Antibacterial activity of AM-1155 against penicillin resistant Streptococcus pneumoniae. J Antimicrob Chemother 1998;41:103-6.
22. Garibaldi RA. Epidemiology of community acquired respiratory tract infections in adults: incidence, etiology and impact. Am J Med 1985;78(6B):32-7.
23. Verheij TJ, Kapstein AA, Mulder JD. Acute bronchitis: etiology, symptoms and treatment. Fam Pract 1989;6:66-9.
24. Huchon GJ, Gialdroni-Grassi G, Leophonte P, Manres AF, Schaberg T, Woodhead M. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J 1996;9(8):1590-5.
25. Grossman RF. How do we achieve cost-effective options in lower respiratory tract infection therapy? Chest 1998;113(3): 205-10.